# Melanoma Vaccine for Dogs: Canine Oral Melanoma Immunotherapy ## Key Takeaways - The Oncept vaccine is a xenogeneic human tyrosinase DNA vaccine designed to stimulate an immune response against canine oral malignant melanoma (OMM) by targeting the tyrosinase enzyme, crucial for melanin production. - Oncept is most effective as an adjunctive therapy for dogs with stage II or III OMM that have achieved local tumor control (complete surgical removal or radiation), with clinical studies showing median survival times of approximately 455 to 510 days in these cases. - The presence of gross (visible) disease at the time of vaccination is a significant negative prognostic factor, indicating reduced efficacy compared to cases with only microscopic disease. - Common side effects of Oncept are mild and localized, typically including temporary pain or swelling at the injection site, and the vaccine is generally well-tolerated. - Experimental immunotherapies, such as CSPG4 DNA vaccines, dendritic cell fusion vaccines, and AAV-based vaccines, are under investigation and may offer future treatment options, often available through clinical trials at veterinary teaching hospitals. - Prognosis for canine OMM is heavily influenced by clinical stage, tumor size, location, and the presence of gross versus microscopic disease, with immunotherapy integrated into a multimodal treatment plan for optimal outcomes. --- Oral malignant melanoma (OMM) is one of the most aggressive and common oral tumors in dogs. For decades, the standard of care relied on surgery and radiation therapy to control the local tumor, but many dogs still succumbed to metastasis. The development of the melanoma vaccine for dogs, specifically the Oncept vaccine, has changed how veterinarians approach this disease. This article provides a definitive, source-grounded review of canine oral melanoma immunotherapy, focusing on how these vaccines work, what the clinical trials show, and what you should discuss with your veterinarian. **Owner Triage Summary:** If your [dog](/knowledge/veterinary-medicine/clinical-methods/dog) has been diagnosed with oral melanoma, the melanoma vaccine (Oncept) is a treatment option that may help extend survival, especially when the primary tumor has been completely removed or treated with radiation. It is not a cure and does not replace surgery or radiotherapy. The vaccine is designed to stimulate your dog's immune system to attack melanoma cells. Clinical studies show median survival times of approximately 12 to 17 months for dogs with stage II or III disease when the vaccine is used alongside local therapies. If your dog has a visible (gross) tumor, the vaccine alone is less effective, but it may still offer some benefit. You should consult a veterinary oncologist to determine if your dog is a candidate for this immunotherapy. ## At a Glance: Canine Oral Melanoma Immunotherapy | Feature | Details | | :--- | :--- | | **Primary Vaccine** | Oncept (xenogeneic human tyrosinase DNA vaccine) [1][2] | | **Target Antigen** | Tyrosinase, an enzyme involved in melanin production [1] | | **Mechanism** | Induces an immune response against tyrosinase-expressing melanoma cells [1] | | **Ideal Candidate** | Dogs with stage II or III oral melanoma with no gross disease (microscopic disease) [2][3] | | **Median Survival Time (MST)** | Approximately 455 days (UK study) to 510 days (US study) when combined with local control [2][3] | | **Common Side Effects** | Mild local reactions at the injection site; generally well-tolerated [1][4] | | **Other Vaccines** | CSPG4 DNA vaccines (experimental), dendritic cell vaccines (experimental), AAV vaccines (experimental) [5][6][7] | | **Cost** | Expensive; often requires a veterinary oncology specialist | | **Key Prognostic Factor** | Presence of gross disease at the time of vaccination is a negative predictor [2] | ## Understanding Canine Oral Melanoma ### The Biology of Oral Melanoma Canine oral melanoma is a malignant tumor arising from melanocytes, the cells that produce pigment (melanin) in the oral mucosa. Unlike some other tumors, melanoma is highly aggressive due to two main characteristics: local invasiveness and a high propensity for distant metastasis [1][3]. The tumor often invades underlying bone, making complete surgical removal difficult. Even with aggressive local therapy, microscopic cancer cells can travel through the blood or lymphatic system to other parts of the body, most commonly the lungs and regional lymph nodes [2]. ### Why Immunotherapy? The high rate of metastasis means that local control alone is often insufficient. This has driven the search for systemic therapies. Chemotherapy has shown limited efficacy in canine melanoma. Immunotherapy, which aims to harness the body's own immune system to fight the cancer, represents a promising strategy because melanoma is considered a potentially immunogenic tumor [1][2]. The goal of a therapeutic vaccine is not to prevent the disease, but to train the immune system to recognize and destroy existing cancer cells. ## The Melanoma Vaccine for Dogs: The Science of Oncept The most widely available and licensed melanoma vaccine for dogs is Oncept. It is a xenogeneic DNA vaccine, meaning it uses DNA from a different species to trigger an immune response [1]. ### How Oncept Works The Oncept vaccine contains a plasmid (a small, circular piece of DNA) that encodes for human tyrosinase. Tyrosinase is an enzyme critical for melanin production and is expressed on the surface of melanoma cells [1]. The key to the vaccine's mechanism is the concept of "xenogeneic" immunization. The human tyrosinase protein is slightly different from the canine tyrosinase protein. When the vaccine is injected, the dog's cells take up the DNA and produce the human tyrosinase protein. The dog's immune system recognizes this human protein as foreign, which triggers a strong immune response. Because the human and canine tyrosinase proteins are similar, the activated immune cells (T-cells and antibodies) will also recognize and attack the dog's own melanoma cells that express tyrosinase [1]. This process breaks the immune system's natural tolerance to the "self" tumor antigen. ### Clinical Evidence for Oncept Several studies have evaluated the efficacy of the Oncept vaccine in dogs with oral melanoma. - **Initial Development:** The development of the xenogeneic DNA vaccine for canine oral melanoma was a landmark in veterinary oncology, demonstrating the potential of this approach [1]. - **US Multi-Institutional Study:** A large retrospective study of 131 dogs treated with Oncept found a median time to progression of 304 days, a median progression-free survival of 260 days, and a median tumor-specific overall survival of 510 days [2]. This study highlighted that the presence of gross disease at the time of vaccination was the most significant negative prognostic indicator. Dogs with adequate local tumor control (complete excision or irradiation of microscopic disease) fared much better than those with visible tumors [2]. - **UK Study:** A retrospective study of 69 dogs in the UK treated with Oncept reported a median survival time of 455 days for dogs with stage I to III disease that had received previous locoregional therapy [3]. Interestingly, this study also observed clinical responses in some patients with macroscopic (visible) disease, suggesting the vaccine may have some activity even in a more advanced setting [3]. - **Surgery and Vaccination:** A review of 32 dogs treated with surgery and the xenogeneic DNA vaccination found an overall median survival time of 335 days [8]. This study noted that the completeness of surgical margins and the delay in receiving the vaccine did not statistically influence survival, though this may have been due to the small number of dogs in the study [8]. ### Oncept Safety and Administration The Oncept vaccine is generally considered safe and well-tolerated. The most commonly reported side effects are mild and local, such as temporary pain or swelling at the injection site [1][4]. The initial safety and efficacy studies confirmed that the vaccine was safe as an adjunctive treatment following surgical excision [4]. The vaccine is administered by a veterinarian as a series of injections, typically every two weeks for a total of four doses, followed by booster vaccinations every six months. ## Other Immunotherapeutic Approaches in Clinical Trials While Oncept is the only licensed vaccine, significant research is exploring other immunotherapeutic strategies for canine oral melanoma. These experimental approaches are often available at veterinary teaching hospitals or through clinical trials. ### CSPG4 DNA Vaccines Chondroitin sulfate proteoglycan 4 (CSPG4) is another tumor antigen that is highly expressed on melanoma cells. Researchers have developed a DNA vaccine that encodes both human and canine portions of the CSPG4 protein (HuDo-CSPG4) to overcome the immune system's tolerance to this self-antigen [7][9]. - **Efficacy:** A veterinary trial involving 80 dogs with surgically resected, CSPG4-positive oral melanoma showed that vaccinated dogs developed a strong immune response against the tumor antigen. The antibody titer was significantly associated with overall survival, and the vaccination appeared to contribute to an improvement in survival compared to control dogs treated with conventional therapies alone [7]. - **Long-Term Survival:** A long-term study of dogs vaccinated with the human CSPG4 DNA vaccine reported significantly longer overall and disease-free survival times compared to non-vaccinated controls [9]. - **Protocol Optimization:** A 2025 study compared two different vaccination protocols for the HuDo-CSPG4 vaccine and found that both protocols resulted in significantly longer overall survival times compared to dogs treated with surgery alone, with a reduced number of vaccinations in one protocol showing similar outcomes [10]. ### Dendritic Cell Vaccines Dendritic cells are the "generals" of the immune system, responsible for presenting antigens to T-cells to initiate an immune response. Researchers have explored using a vaccine that fuses allogeneic dendritic cells with autologous tumor cells (from the dog's own tumor). - **Safety and Feasibility:** A pilot study demonstrated that this dendritic cell fusion vaccine, when given alone or in combination with radiotherapy, was safe and well-tolerated in dogs with oral melanoma [11][5]. The most common side effects were mild, radiation-related mucositis [5]. - **Preliminary Efficacy:** The studies showed that the treatment was potentially effective. The median progression-free survival for dogs receiving the combination of vaccine and radiotherapy was 146.5 days [11]. While the numbers were small, the research supports further investigation into this treatment approach [11][5]. ### AAV and Viral Vector Vaccines Another area of research involves using viral vectors, like adeno-associated viruses (AAV), to deliver multiple melanoma antigens to the immune system. - **Multivalent Approach:** A 2026 preclinical study evaluated a multivalent AAV cancer vaccine encoding for three melanoma antigens (GP100, tyrosinase, and TRP-1) in dogs with spontaneous oral melanoma [6]. The vaccine was safe, with no adverse effects, and successfully induced antigen-specific T-cell responses in most dogs. While survival times varied, three of the eight dogs were disease-free by the end of the study, and two dogs survived over 800 days after vaccination [6]. - **Checkpoint Blockade Vaccines:** Other research has focused on vaccines that combine melanoma antigens with inhibitors of immune checkpoints to enhance the immune response. A safety and immunogenicity trial of a viral vector-based vaccine in healthy dogs showed that it was well-tolerated and increased the frequency of melanoma-specific T-cells [12]. ## Integrating Immunotherapy with Standard of Care Immunotherapy is rarely used alone. The best outcomes are achieved when it is integrated into a multimodality treatment plan. ### Surgery and Radiation Surgery is the primary treatment for oral melanoma if the tumor can be completely removed. Radiation therapy is highly effective for local control, especially when surgery is incomplete or the tumor is not resectable. A study on hypofractionated radiotherapy found that T-stage was the most significant factor affecting survival, but the use of the Oncept vaccine was also evaluated in the treatment protocol [13]. The combination of surgery and/or radiation with the Oncept vaccine is the standard of care for dogs with locally controlled disease [2][3]. ### The Role of Elective Nodal Irradiation A 2025 study investigated whether prophylactically irradiating clinically uninvolved lymph nodes (elective nodal irradiation, ENI) in dogs undergoing hypofractionated radiotherapy improved outcomes. The study found no significant difference in 1-year nodal or distant progression-free intervals between dogs that received ENI and those that did not. This suggests that ENI may not be necessary for all dogs, and the decision should be made on a case-by-case basis [13]. ### Chemotherapy and Other Systemic Agents Traditional chemotherapy has limited efficacy in canine melanoma. However, metronomic chemotherapy (low-dose, frequent administration) is sometimes used in combination with immunotherapy. A study evaluating inflammatory markers in dogs treated with an autologous antitumor vaccine with or without metronomic chemotherapy found no significant difference in progression-free or overall survival between the two groups [14]. However, the study identified that the C-reactive-protein-to-albumin ratio and circulating Tregs were associated with survival, suggesting these could be used as prognostic markers [14]. ### Immune Checkpoint Inhibitors Beyond vaccines, immune checkpoint inhibitors (ICIs) are a powerful class of immunotherapy that work by "releasing the brakes" on the immune system. A 2025 study evaluated the anti-PD-L1 antibody HFC-L1/c4G12 in dogs with pulmonary metastatic oral melanoma. The study found that higher doses (5 or 10 mg/kg) resulted in numerically longer median overall survival compared to the lower dose (2 mg/kg), with similar safety profiles across all groups. This suggests that ICIs may be a promising future treatment option for dogs with advanced disease [15]. ## Prognosis and Survival Data The prognosis for dogs with oral melanoma is highly variable and depends on several factors. It is important to have an honest conversation with your veterinary oncologist about your dog's specific situation. ### Key Prognostic Factors - **Clinical Stage:** The presence and extent of the primary tumor (T-stage), lymph node involvement (N-stage), and distant metastasis (M-stage) are the most important prognostic factors. Higher stages (II, III, IV) are associated with a worse prognosis [2][14]. - **Gross vs. Microscopic Disease:** Dogs with no visible tumor after surgery or radiation (microscopic disease) have significantly better outcomes with the vaccine than dogs with visible (gross) tumors [2]. - **Tumor Size and Location:** Primary tumors larger than 2 cm and tumors located in the caudal (back) part of the oral cavity are associated with a poorer prognosis [2]. - **Inflammatory Markers:** Studies have shown that a higher C-reactive-protein-to-albumin ratio (CRP/ALB) before treatment is associated with shorter progression-free and overall survival [14]. This suggests that systemic inflammation can impact the response to immunotherapy. ### Survival Times with Oncept The following table summarizes survival data from key studies on the Oncept vaccine: | Study | Patient Population | Median Survival Time (MST) | | :--- | :--- | :--- | | Turek et al. (2020) [2] | 131 dogs (all stages, with local control) | 510 days | | Verganti et al. (2017) [3] | 69 dogs (stage I-III, with locoregional therapy) | 455 days | | Treggiari et al. (2016) [8] | 32 dogs (surgery + vaccine) | 335 days | These studies consistently show that the vaccine, when used with local control, provides a median survival time of roughly 1 to 1.5 years. It is important to remember that these are median times, meaning many dogs live longer, and some will unfortunately live shorter. ## Safety, Side Effects, and Home Care ### What to Expect After Vaccination The Oncept vaccine is very safe. The most common side effects are mild and transient, including: - Pain or swelling at the injection site. - Mild lethargy for a day or two. Serious side effects are rare. You should monitor your dog after vaccination and contact your veterinarian if you notice any severe or persistent reactions, such as facial swelling, difficulty breathing, or vomiting. ### Unsafe Home Remedies There are no proven home remedies for treating oral melanoma. **Do not** attempt to treat your dog's tumor with any over-the-counter products, essential oils, or human medications. These can be toxic and delay effective treatment. The only safe and effective treatments are those prescribed and administered by a licensed veterinarian. ## Limitations and When to Contact a Veterinarian This article provides a detailed overview of melanoma vaccines for dogs, but it cannot predict what will happen with your individual dog. The response to immunotherapy is highly variable. Breed, age, and overall health can influence outcomes, but no online article can account for the specific pathology of your dog's tumor or its unique genetic makeup. **You should contact your veterinarian or a veterinary oncologist immediately if:** 1. Your dog has a new or growing mass in its mouth. 2. Your dog has difficulty eating, drooling excessively, or has bad breath. 3. Your dog has bleeding from the mouth. 4. Your dog is experiencing side effects from the vaccine that are severe or lasting more than a few days. 5. You have any questions about your dog's treatment plan or prognosis. ## Frequently Asked Questions ### 1. What is the melanoma vaccine for dogs? The melanoma vaccine for dogs, most commonly known as Oncept, is a therapeutic immunotherapy designed to treat oral malignant melanoma. It is a xenogeneic DNA vaccine that uses human tyrosinase DNA to stimulate the dog's immune system to attack its own melanoma cells [1]. ### 2. How effective is the Oncept vaccine for canine oral melanoma? The Oncept vaccine is most effective when used as an adjunctive treatment after local control (surgery or radiation) of the primary tumor. Studies show median survival times of 455 to 510 days in these dogs [2][3]. It is less effective in dogs with visible (gross) tumors [2]. ### 3. Is the melanoma vaccine a cure for oral melanoma in dogs? No, the melanoma vaccine is not a cure. It is a treatment that aims to prolong survival and delay the progression of the disease by stimulating the immune system. It is most effective when combined with surgery and/or radiation therapy [2][3]. ### 4. What are the side effects of the canine melanoma vaccine? The Oncept vaccine is generally very well-tolerated. The most common side effects are mild, such as temporary pain or swelling at the injection site. Serious side effects are rare [1][4]. ### 5. How much does the melanoma vaccine for dogs cost? The cost of the Oncept vaccine is significant and can vary depending on your location and veterinary clinic. It typically involves an initial series of four injections and then booster vaccinations. You should request a detailed cost estimate from your veterinary oncologist. ### 6. Are there alternative immunotherapy options to Oncept? Yes, there are several experimental immunotherapies being studied in clinical trials. These include DNA vaccines targeting CSPG4 [7][10][9], dendritic cell fusion vaccines [11][5], and AAV-based vaccines [6]. These may be available at veterinary teaching hospitals. ### 7. What is the survival time for a dog with oral melanoma without treatment? Without treatment, the prognosis for oral melanoma is very poor, with survival times often only a few months due to local invasion and rapid metastasis. The vaccine, combined with local therapy, has been shown to significantly extend survival compared to historical controls [2][3][7]. ### 8. Can the melanoma vaccine be used for other types of cancer in dogs? The Oncept vaccine is specifically licensed for the treatment of oral melanoma in dogs with stage II or III locally controlled disease. While research is exploring other targets, it is not currently approved for other cancer types. Other experimental vaccines are being developed for different cancers, but they are not commercially available [1][2]. --- ## Related Clinical & Scientific Guides * [Lymphoma in Cats: High-Grade vs Low-Grade GI Alimentary Lymphoma](/knowledge/veterinary-medicine/dermatology-oncology/lymphoma-in-cats-high-grade-vs-low-grade-gi-alimentary-lymphoma 2) * [Lymphoma in Cats: High-Grade vs Low-Grade GI Alimentary Lymphoma](/knowledge/veterinary-medicine/dermatology-oncology/lymphoma-in-cats-high-grade-vs-low-grade-gi-alimentary-lymphoma) * [Symmetrical Lupoid Onychodystrophy SLO: Nails Sloughing and Omega-3 Dose](/knowledge/veterinary-medicine/dermatology-oncology/symmetrical-lupoid-onychodystrophy-slo-nails-sloughing-and-omega-3-dose)